Safety Considerations at Higher Semaglutide Doses While the 2.4 mg dose is established as safe and effective in clinical trials, higher doses are not routinely used for weight loss because efficacy plateaus and side effect risk increases
A real-world cohort study of 2,410 semaglutide patients at an academic obesity medicine center found that 78% of those who required a temporary dose reduction for GI intolerance eventually reached the target 2.4 mg dose within 6 months [14]
If you're considering medication to support your weight loss journey, you can meet with a QuickMD doctor today and explore if Wegovy is the right fit for you
But that understanding brings little comfort when you still have significant weight to lose and the progress has stalled completely
Social interaction test (SI) The social interaction apparatus consisted of a transparent acrylic arena divided into three equally sized chambers connected with guillotine doors
With increasing frequency over the past few years, optometrists across the country have gotten referrals from internists requesting baseline diabetic retinopathy (DR) screenings for patients about to start therapy with one of the glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists such as semaglutide (Ozempic, Novo Nordisk), tirzepatide (Mounjaro, Eli Lilly) and dulaglutide (Trulicity, Eli Lilly